Jonathan Chang
Stock Analyst at Leerink Partners
(0.64)
# 3,706
Out of 4,814 analysts
86
Total ratings
28.77%
Success rate
-19.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $19.55 | +38.11% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $28.54 | +159.29% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $3.29 | +234.35% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $15.56 | +227.76% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $5.06 | +1,383.68% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $7.96 | +327.14% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.35 | +580.27% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $36.75 | -18.37% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.27 | +844.88% | 8 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $0.35 | +3,848.11% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $4.26 | +510.33% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $28.86 | +229.18% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.24 | +1,136.09% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $5.88 | +376.19% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $9.69 | +446.96% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $19.55
Upside: +38.11%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $28.54
Upside: +159.29%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $3.29
Upside: +234.35%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $15.56
Upside: +227.76%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $5.06
Upside: +1,383.68%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $7.96
Upside: +327.14%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.35
Upside: +580.27%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $36.75
Upside: -18.37%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.27
Upside: +844.88%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.35
Upside: +3,848.11%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $4.26
Upside: +510.33%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $28.86
Upside: +229.18%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.24
Upside: +1,136.09%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $5.88
Upside: +376.19%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $9.69
Upside: +446.96%